50 results about "Interleukin receptor" patented technology

The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

The present invention relates to multispecific antigen binding proteins that comprise an antigen-binding regions specific for a tumor-associated antigen (TAA), an antigen-binding region that specifically binds an epitope of a γδ T cell receptor (TCR), a γδ T cell-activating cytokine, and optionally, a γδ T cell co-stimulatory agonist. The γδ T cell-activating cytokine preferably is at least 5 one of an interleukin 21 receptor (IL21R) agonist and an interleukin 15 receptor (IL15R) agonist. The γδ T cell co-stimulatory agonist cytokine preferably is at least one of a 4-1BB agonist, a CD27 agonist and a GITR agonist. The multispecific antigen binding proteins of the invention specifically redirect and activate γδ T cell to lyse targeted tumor cells. The invention further relates to the use of such multispecific antigen binding proteins in the treatment of cancer, preferably a cancer 10 expressing the TAA.

The present application relates to a novel antibody or antibody fragment thereof of interleukin-23 receptor, which can effectively bind IL-23R, block the binding of IL-23R and human IL-23 alpha / IL-12 beta heterodimer ligand, and has good application prospect. The antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises VH CDR1, VH CDR2 and VH CDR3, and the light chain variable region comprises VL CDR1, VL CDR2 and VL CDR3, wherein VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 3, 13 or 23, VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 4, 14 or 24, VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 5, 15 or 25; VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 8, 18 or 28, VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, 19 or 29, and VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 10, 20 or 30.

This invention relates to antibody-drug conjugates and their uses. An antibody-drug conjugate having a structure represented by formula (I) is provided: Ab-(L-D) n (I), wherein Ab is an antibody against the interleukin-6 receptor or an antigen-binding fragment thereof, said antibody or antigen-binding fragment comprising at least one light chain and at least one heavy chain as described herein, and the use of the antibody-drug conjugate. The antibody-drug conjugate of the present invention can significantly reduce the dosage, improve patient tolerability, and reduce adverse reactions.

The present invention provides for chimeric antigen receptor constructs capable of being expressed in dendritic cells (DCs), and DCs modified to express one or more chimeric antigen receptors (CARs) as well as compositions comprising these modified DCs and methods of stimulating an adaptive immune response in a subject. The intracellular domain of the CAR comprises a toll-interleukin receptor (TIL) intracellular signalling domain and a costimulating domain selected from CD3 signalling domain, CD28 signalling domain and a combined CD28 and CD3 signalling domain.

The present invention relates to a peptide inhibitor of an interleukin-23 receptor and a use thereof. In particular, the present invention relates to peptide inhibitors of the interleukin-23 receptor, stereoisomers or pharmaceutically acceptable salts or solvates thereof, pharmaceutical compositions thereof, and uses of the peptide inhibitors in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

The present invention relates to compounds that are peptide inhibitors of the interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), psoriasis and psoriatic arthritis. The compound has good physical and chemical stability in the gastrointestinal tract.

The present invention relates to a peptide inhibitor of interleukin-23 receptor, and a use thereof. In particular, it relates to a peptide inhibitor of interleukin-23 receptor, a stereoisomer, pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition thereof, and a use of the peptide inhibitor in treating or preventing diseases or conditions comprising inflammatory bowel disease, Crohn's disease, and psoriasis.

The present invention relates to novel cyclic peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, methods and / or uses for treatment of autoimmune inflammation and related diseases and disorders.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

Methods for treating bullous pemphigoid in a subject are provided. In one aspect, the methods comprise administering to a subject having bullous pemphigoid one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

Modified natural killer (NK) cells or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express thrombopoietin receptors, erythropoietin receptors, or chimeric peptides comprising an extracellular domain, a transmembrane domain, and an intracellular domain including an intracellular signaling domain of an interleukin receptor. Methods for treating cancer subjects are also provided, comprising administering modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or an erythropoietin receptor agonist, and in some instances, in combination with interleukin-2, particularly reduced or low doses of IL-2.

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.

The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and three light chain complementarity determining regions CDR-LI, CDR-L2 and CDR-L3, and the amino acid sequences of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3 are as shown in SEQ ID NO: 1 to SEQ ID NO: 6, respectively. Compared with Spesolimab, the monoclonal antibody has comparable binding affinity to human IL-36R, and the neutralizing activity of the monoclonal antibody at the cellular level is superior to that of Spesolimab.

This invention provides an antibody targeting the human interleukin-6 receptor, its applications, and products, belonging to the field of protein engineering technology. The antibody provided by this invention comprises: any one or more of HCDR1, HCDR2, and HCDR3 with sequences as shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively, and / or any one or more of LCDR1, LCDR2, and LCDR3 with sequences as shown in SEQ ID NO.4, SEQ ID NO.5, and SEQ ID NO.6, respectively. The antibody targeting the human interleukin-6 receptor provided by this invention has high affinity, good blocking effect, and excellent safety.

The application provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and an application thereof. The anti-human interleukin 36 receptor (IL-36R) monoclonal antibody provided by the application comprises three heavy chain complementarity determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementarity determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein (a) the amino acid sequence of CDR-H1 is shown as SEQ ID NO:1; (b) the amino acid sequence of CDR-H2 is shown as SEQ ID NO:2; (c) the amino acid sequence of CDR-H3 is shown as SEQ ID NO:3; (d) the amino acid sequence of CDR-L1 is shown as SEQ ID NO:4; (e) the amino acid sequence of CDR-L2 is shown as SEQ ID NO:5; and (f) the amino acid sequence of CDR-L3 is shown as SEQ ID NO:6. The anti-human interleukin 36 receptor (IL-36R) monoclonal antibody has the same affinity to human IL-36R as Spesolimab (prepared according to the patent publication sequence table), and has better neutralization activity at the cell level than Spesolimab, and is expected to exhibit good clinical effects in the prevention and treatment of related diseases.

The present invention relates to a peptide inhibitor of the interleukin-23 receptor and the use thereof. Specifically, the present invention relates to a peptide inhibitor of the interleukin-23 receptor, a stereoisomer or pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition thereof, and the use of the peptide inhibitor in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease, and psoriasis.

The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.

This invention discloses a neutralizing nanobody targeting soluble interleukin-17 receptor D (sIL-17RD), its preparation method, and its applications. The heavy chain variable region (VHH) of this nanobody contains a heavy chain complementarity-determining region 3 (CDR-H3) that specifically binds to sIL-17RD, with a length of 10 amino acids and containing 2–6 lysine residues. This invention provides four nanobodies: CQ5, CQ13, CQ11, and CQ6, corresponding to well-defined CDR-H1, CDR-H2, and CDR-H3 sequence combinations. This nanobody can specifically bind to and neutralize the biological activity of sIL-17RD, reducing chondrocyte death, promoting proliferation, and maintaining extracellular matrix homeostasis by inhibiting the P2rx7-NLRP3 inflammasome-mediated chondrocyte pyroptosis pathway. This invention also protects the nucleic acid encoding this nanobody, the recombinant expression vector, the host cell, the pharmaceutical composition, and the preparation method. The nanobodies described can be used to prepare drugs for the prevention and treatment of inflammatory osteoarthritis and other osteoarthritis. They can inhibit synovitis, reverse cartilage and subchondral bone degeneration, and relieve pain, showing promising application prospects.

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The present invention relates to therapeutic and / or prophylactic agents for ocular inflammatory disease, which comprise an interleukin 6 (IL-6) receptor inhibitor as an active ingredient.

The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.

The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and three light chain complementarity determining regions CDR-L1, CDR-L2 and CDR-L3, and the amino acid sequences of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3 are as shown in SEQ ID NO: 1 to SEQ ID NO: 6, respectively. Compared with Spesolimab, the monoclonal antibody has comparable binding affinity to human IL-36R, and the neutralizing activity of the monoclonal antibody at the cellular level is superior to that of Spesolimab.

This document provides methods and materials involved in promoting bone growth. For example, this document provides vectors designed to express (a) a nucleotide sequence encoding a bone morphogenetic protein 2 (BMP2) polypeptide and / or (b) a nucleotide sequence encoding an interleukin-1 receptor antagonist (IL-1Ra) polypeptide for promoting bone growth. In some cases, one or more vectors provided herein can be administered to a mammal (e.g., a human) having a disease, disorder, or condition associated with bone loss to treat the mammal. For example, a population of a single vector provided herein can be used to increase expression of a BMP2 polypeptide and an IL-1Ra polypeptide by cells within a mammal (e.g., a human) having a disease, disorder, or condition associated with bone loss to promote bone growth within the mammal.

This patent document provides novel compounds as inhibitors of interleukin- 1 receptor-associated kinases such as IRAKI and IRAK4. Also disclosed are methods of treating diseases associated with abnormal expression or activities of kinases of IRAK family.

Provided are chimeric cell surface receptors comprising an extracellular domain of a cell surface receptor and an intracellular domain of a different cell surface receptor. In certain embodiments, a chimeric cell surface receptor of the present disclosure comprises an extracellular domain of a tumor necrosis factor receptor (TNFR) and an intracellular domain of a different TNFR or a receptor other than a TNFR. According to other embodiments, a chimeric cell surface receptor of the present disclosure comprises an extracellular domain of an interleukin receptor (ILR) and an intracellular domain of a different ILR or a receptor other than an ILR. Also provided are cells (e.g., immune effector cells) that express a chimeric cell surface receptor of the present disclosure. Also provided are methods of using such cells to treat a condition (e.g., cancer, infection, and / or the like) in a subject in need thereof.

Provided are an interleukin receptor antagonist and an application thereof, and specifically provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The provided compound exhibits potent biological activity and good pharmacokinetic properties, or demonstrates good efficacy in animal pharmacodynamic studies. c[X4-X5-X6-X7-X8-X9]-X10-X11-X12-X13-X14-X15-X16 (I)

The present invention relates to novel lipidated peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salts, solvates and / or other forms thereof, corresponding pharmaceutical compositions, methods and / or uses of the IL-23R inhibitors for treatment of autoimmune inflammation diseases and / or related disorders.

Described herein are antibodies, or antigen binding fragments thereof, that bind thymic stromal lymphopoietin (TSLP) and interleukin (IL)-4Rα in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-4Rα and TSLP biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-TSLP and anti- IL-4Rα antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP and / or IL-4.